Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Pfizer Inc. (PFE : NYSE)
 
 • Company Description   
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.

Number of Employees: 75,000

 
 • Price / Volume Information   
Yesterday's Closing Price: $24.54 Daily Weekly Monthly
20 Day Moving Average: 41,055,400 shares
Shares Outstanding: 5,699.44 (millions)
Market Capitalization: $139,864.36 (millions)
Beta: 0.35
52 Week High: $28.75
52 Week Low: $23.11
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 3.68% 2.91%
12 Week -8.09% -10.61%
Year To Date -1.45% -7.19%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
66 HUDSON BOULEVARD EAST
-
NEW YORK,NY 10001
USA
ph: 212-733-2323
fax: 302-655-5049
ir@pfizer.com http://www.pfizer.com
 
 • General Corporate Information   
Officers
Albert Bourla - Chief Executive Officer; Chairman and Director
David M. Denton - Chief Financial Officer; Executive Vice President
Jennifer B. Damico - Senior Vice President and Controller
Ronald E. Blaylock - Director
Mortimer J. Buckley - Director

Peer Information
Pfizer Inc. (AGN.)
Pfizer Inc. (NVS)
Pfizer Inc. (NVO)
Pfizer Inc. (LLY)
Pfizer Inc. (RHHBY)
Pfizer Inc. (JNJ)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Large Cap Pharma
Sector: Medical
CUSIP: 717081103
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/26
Next Expected EPS Date: 08/04/26
Share - Related Items
Shares Outstanding: 5,699.44
Most Recent Split Date: 7.00 (3.00:1)
Beta: 0.35
Market Capitalization: $139,864.36 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 7.01%
Current Fiscal Quarter EPS Consensus Estimate: $0.87 Indicated Annual Dividend: $1.72
Current Fiscal Year EPS Consensus Estimate: $2.96 Payout Ratio: 0.56
Number of Estimates in the Fiscal Year Consensus: 10.00 Change In Payout Ratio: 0.03
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: 05/08/2026 - $0.43
Next EPS Report Date: 08/04/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 8.30
Trailing 12 Months: 8.02
PEG Ratio: -
Price Ratios
Price/Book: 1.55
Price/Cash Flow: 5.58
Price / Sales: 2.21
EPS Growth
vs. Year Ago Period: -18.48%
vs. Previous Quarter: 13.64%
Sales Growth
vs. Year Ago Period: 5.37%
vs. Previous Quarter: -17.69%
ROE
06/30/26 - -
03/31/26 - 19.44
12/31/25 - 20.48
ROA
06/30/26 - -
03/31/26 - 8.41
12/31/25 - 8.86
Current Ratio
06/30/26 - -
03/31/26 - 1.25
12/31/25 - 1.16
Quick Ratio
06/30/26 - -
03/31/26 - 0.94
12/31/25 - 0.87
Operating Margin
06/30/26 - -
03/31/26 - 27.58
12/31/25 - 29.41
Net Margin
06/30/26 - -
03/31/26 - 11.83
12/31/25 - 12.42
Pre-Tax Margin
06/30/26 - -
03/31/26 - 12.48
12/31/25 - 12.02
Book Value
06/30/26 - -
03/31/26 - 15.86
12/31/25 - 15.26
Inventory Turnover
06/30/26 - -
03/31/26 - 1.51
12/31/25 - 1.44
Debt-to-Equity
06/30/26 - -
03/31/26 - 0.67
12/31/25 - 0.71
Debt-to-Capital
06/30/26 - -
03/31/26 - 40.12
12/31/25 - 41.53
 

Powered by Zacks Investment Research ©